Modulation of lipid metabolism for protein production
AssigneeLonza Ltd.
InventorsJames Budge, Christopher Mark Smales, Tanya Jeane Knight, Robert Young
Life of this patent
Estimating the term…
Abstract
The present disclosure features methods and compositions for modulating lipid metabolism to achieve improved production and quality of recombinant products, such as next generation biologics. Modulation of lipid metabolism as described herein includes, for example, introducing a lipid metabolism modulator described herein to a cell or a cell-free system. Also encompassed by the present disclosure are engineered cells with improved production capacity and improved product quality, methods for engineering such cells, and preparations and mixtures comprising the products from such cells.
Claims19
A eukaryotic cell comprising:
- (i) a first exogenous nucleic acid encoding a first lipid metabolism modulator (LMM), wherein the first LMM comprises stearoyl CoA desaturase-1 (SCD-1), or a functional fragment or isoform thereof, the first exogenous nucleic acid being operably linked to a promoter that directs expression of the first LMM in the cell;
- and
- (ii) a second exogenous nucleic acid encoding a recombinant therapeutic polypeptide selected from an antibody, an antibody fragment, a hormone, a blood clotting factor, a cytokine or a protein vaccine, the second exogenous nucleic acid being operably linked to a promoter that directs expression of the recombinant therapeutic polypeptide in the cell.
A method for producing a recombinant therapeutic polypeptide in a cell, the method comprising:
- providing a eukaryotic cell comprising a first exogenous nucleic acid encoding a first lipid metabolism modulator (LMM) comprising stearoyl CoA desaturase-1 (SCD-1), or a functional fragment or isoform thereof;
- and a second exogenous nucleic acid encoding the recombinant therapeutic polypeptide, wherein the recombinant therapeutic polypeptide is selected from an antibody, an antibody fragment, a hormone, a blood clotting factor, a cytokine or a protein vaccine;
- and
- (ii) culturing the cell under conditions where the first LMM and the recombinant therapeutic polypeptide are expressed,
- thereby producing the recombinant therapeutic polypeptide.
Dependencies are inferred from the claim text.